Is Biovie Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: BIVI) stock is to Buy BIVI stock.
Out of 1 analyst, 0 (0%) are recommending BIVI as a Strong Buy, 1 (100%) are recommending BIVI as a Buy, 0 (0%) are recommending BIVI as a Hold, 0 (0%) are recommending BIVI as a Sell, and 0 (0%) are recommending BIVI as a Strong Sell.
What is BIVI's revenue growth forecast for 2026-2026?
(NASDAQ: BIVI) Biovie's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Biovie's revenue in 2024 is $0.
In 2026, BIVI is forecast to generate $510,350,054 in revenue, with the lowest revenue forecast at $510,350,054 and the highest revenue forecast at $510,350,054.
What is BIVI's forecast return on assets (ROA) for 2024-2027?
(NASDAQ: BIVI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.
What is BIVI's Price Target?
According to 1 Wall Street analyst that have issued a 1 year BIVI price target, the average BIVI price target is $5.00, with the highest BIVI stock price forecast at $5.00 and the lowest BIVI stock price forecast at $5.00.
The Wall Street analyst predicted that Biovie's share price could reach $5.00 by Nov 30, 2024. The average Biovie stock price prediction forecasts a potential upside of 836.33% from the current BIVI share price of $0.53.
What is BIVI's forecast return on equity (ROE) for 2024-2027?
(NASDAQ: BIVI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.